$-0.32 EPS Expected for Sarepta Therapeutics, Inc. (SRPT)

April 16, 2018 - By Michael Collier

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 1.22 in 2017 Q4. Its down 1.66, from 2.88 in 2017Q3. It dived, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
Fuller And Thaler Asset invested 0.1% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Qvt Financial Lp has 17,231 shares. Pinnacle Associates Limited has 303,006 shares. 55,446 were reported by One Trading Limited Partnership. Smith Asset Management Gru L P holds 0.02% or 9,160 shares. Dekabank Deutsche Girozentrale holds 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 24,733 shares. Moreover, Point72 Asset Lp has 0.14% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 579,757 shares. California State Teachers Retirement stated it has 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 27,607 are owned by Jane Street Grp Incorporated Ltd Liability. Atlantic Tru Group Ltd Liability Corp invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Pictet Asset Mngmt Ltd holds 40,200 shares. Private Ocean Limited Liability has 200 shares. Emerald Advisers Pa invested in 886,979 shares or 1.9% of the stock. Rhumbline Advisers accumulated 61,542 shares. D E Shaw Com has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.32 EPS on April, 26.They anticipate $0.41 EPS change or 56.16 % from last quarter’s $-0.73 EPS. After having $-0.37 EPS previously, Sarepta Therapeutics, Inc.’s analysts see -13.51 % EPS growth. The stock decreased 1.96% or $1.58 during the last trading session, reaching $79.22. About 493,369 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 16, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Sarepta Therapeutics had 25 analyst reports since October 17, 2017 according to SRatingsIntel. As per Wednesday, March 21, the company rating was downgraded by Morgan Stanley. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Monday, March 12 by H.C. Wainwright. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Outperform” rating by Credit Suisse on Tuesday, March 13. The company was maintained on Monday, March 12 by Piper Jaffray. The stock has “Equal-Weight” rating by Barclays Capital on Thursday, October 26. Piper Jaffray maintained it with “Buy” rating and $70.0 target in Friday, March 2 report. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, March 13 report. Janney Capital initiated the stock with “Buy” rating in Wednesday, January 3 report. As per Thursday, October 26, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating given on Friday, January 19 by Leerink Swann.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $5.15 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: